Paoletta

Quick links to important sections

Paoletta

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paoletta

Paoletta is a prescription medication designed for oral use, classified as a combined hormonal contraceptive.

Property Description
Active Ingredients Dienogest, Ethinyl Estradiol
Form Film-coated tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Primary Purpose Pregnancy prevention (Contraception)
Origin Synthetic/Semisynthetic

What Type of Medicine is Paoletta?

Paoletta is a prescription-only medication categorized as a Combined Hormonal Contraceptive (CHC), specifically positioned for use in women of reproductive age seeking reliable birth control. It belongs to the high-level pharmacological group of Progestogens and estrogens, which are utilized in a fixed combination for systemic hormonal management. The drug is presented as a film-coated tablet designed for oral administration.

This combined hormonal approach is recognized for its effectiveness in pregnancy prevention. The medication is essentially an oral contraceptive pill; therefore, its general purpose is to provide highly effective contraception.


Composition: Dienogest, Ethinyl Estradiol, and Origin

Paoletta is a fixed-dose combination product containing two synthetic active ingredients: Ethinyl Estradiol and Dienogest. Ethinyl Estradiol serves as the estrogenic component, while Dienogest functions as the progestin. Dienogest is a noteworthy differentiating factor as a fourth-generation progestin that exhibits unique antiandrogenic properties.

This medicine is supplied in a precise, consistent ratio of the two hormones in every tablet. This structure guarantees that a specific, predetermined amount of both the Ethinyl Estradiol and Dienogest is delivered. The oral tablet structure requires various pharmaceutical excipients—inert components—to create the final structure suitable for ingestion.


Primary Purpose and High-Level Action

The primary purpose of Paoletta is effective pregnancy prevention through systemic hormonal regulation. The combined effect of the synthetic estrogen and progestin works together to suppress ovulation, preventing the monthly release of an egg, which is the essential prerequisite for fertilization.

This contraceptive action is reinforced by secondary mechanisms: the thickening of the cervical mucus and modification of the endometrial lining. This dual-action approach is consistent with the intended use of this type of hormonal combination as a comprehensive contraceptive agent.

Regulatory References

  1. Contraception and Birth Control Methods - NIH (NICHD)

What side effects are possible with Paoletta?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety information for this medicine, strictly based on authoritative government regulatory documents.

Adverse Reaction Scope

Official regulatory reports categorize adverse events by the affected System-Organ Class, noting issues that affect the central nervous system, cardiovascular system, and respiratory system. The most significant safety findings are linked to serious health consequences reported after exposure.

Category Documented Safety Information
Serious Adverse Reactions Seizures, loss of consciousness, severe respiratory depression (slowed or stopped breathing), cardiac toxicity, and death have been reported, primarily associated with high-dose use.
System-Organ Class Adverse effects reported include agitation, drowsiness, confusion, rapid heartbeat, high blood pressure, and gastrointestinal symptoms like nausea and vomiting.
Dose- or Exposure-Related Patterns The most severe adverse reactions are explicitly linked to ingestion of doses significantly exceeding typical therapeutic levels or concurrent exposure with other substances.
Safety-Related Limitations Regulatory findings formally document a high potential for misuse, abuse, and the development of physical dependence and withdrawal symptoms.

Regulatory Safety Summary

The medicine's safety profile is defined by restrictions stemming from its documented potential for abuse and dependence, particularly among individuals with a history of opioid use. Official documentation highlights that severe adverse events, including life-threatening toxicities, occur most frequently when the substance is consumed in doses far above those used in its approved foreign contexts. Continuous regulatory monitoring and warnings focus on preventing consumer exposure to unapproved products containing this ingredient.

Overdose and Emergency Response

The official regulatory documentation for Paoletta (Dienogest/Ethinyl Estradiol), a combined hormonal contraceptive, defines the overdose profile primarily by documented, non-life-threatening clinical manifestations. Acute overexposure is generally characterized by expected gastrointestinal disturbances, including nausea and vomiting. In females, withdrawal bleeding is also a recognized hormonal manifestation that may occur following overdosage. Prescribing information explicitly notes that there have been no reports of serious ill effects resulting from overdosage, a finding that includes instances of accidental ingestion by children.

Despite this low acute toxicity classification, the regulatory requirement remains consistent: individuals who suspect an overdose or massive overexposure must immediately seek emergency medical attention and should contact a national Poison Help line for specific guidance. Management of overdosage is defined as entirely symptomatic and supportive treatment, as no specific antidote is known to exist for this combination product. This supportive approach may require clinical monitoring of vital signs and laboratory assessments.

Therapeutic Uses of Paoletta

Paoletta is commonly used across therapeutic domains that require effective contraception and the management of associated hormone-driven symptoms. The therapeutic scope extends beyond pregnancy prevention to address specific discomforts that commonly affect women of reproductive age, including the management of acne.

The primary purpose is its use in the domain of contraception, which assists with maintaining functional stability. It is also used for managing symptoms related to heavy or prolonged menstrual blood loss (menorrhagia), menstrual cramps (dysmenorrhea), and androgen-related skin issues like acne and seborrhoea. This is relevant in clinical settings that involve recurrent or episodic manifestations.

This medication assists with easing the overall symptom load and helps address symptom clusters that may become intense or disruptive, which generally helps patients cope more steadily with symptom fluctuations.


Quick Fact: Focus on Menstrual Symptoms Paoletta is relevant for easing symptoms that interfere with daily comfort, such as heavy bleeding and chronic pelvic pain, and may assist with maintaining functional stability during difficult episodes.

Regulatory References

  1. European Medicines Agency (EMA) on Dienogest/Ethinylestradiol

Eligibility and Restrictions for Use

Paoletta (tapentadol) is a centrally-acting opioid analgesic indicated for managing moderate to severe acute pain or chronic pain that is severe enough to require daily, around-the-clock, long-term opioid treatment, and for which alternative options have been inadequate. It is approved for use in adults and in some formulations, in pediatric patients aged six years and older.

Contraindications and Patient Populations

Certain conditions and patient circumstances make the use of Paoletta unsafe and are considered contraindications. Physicians must thoroughly review a patient's medical history before prescribing this medication.

Do Not Use If You Have: Use With Caution:
Severe respiratory depression or acute/severe bronchial asthma. Severe renal or hepatic impairment; a reduced dose may be necessary.
Known or suspected gastrointestinal obstruction (e.g., paralytic ileus). History of head injury, seizures, or conditions with increased intracranial pressure.
Concurrently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. In conjunction with other Central Nervous System (CNS) depressants (e.g., alcohol, sedatives).
Known hypersensitivity (e.g., anaphylaxis, angioedema) to tapentadol or any component of the formulation. The elderly, due to higher risk of adverse effects, decreased organ function, and drug interactions.

Pregnancy and Breastfeeding: Paoletta should be used during pregnancy only if the potential benefit justifies the risk to the fetus, as it can cause Neonatal Opioid Withdrawal Syndrome (NOWS). It is not recommended for use in breastfeeding mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Paoletta as described in government regulatory sources. The profile is primarily defined by the way other substances affect the metabolic clearance of the hormone components, Ethinyl Estradiol and Dienogest.

Prohibited and Restricted Combinations

Co-administration with strong hepatic enzyme inducers is restricted because these substances significantly accelerate the metabolic breakdown of the hormones, leading to a loss of contraceptive efficacy. Medicines and substances documented to cause this interaction include Carbamazepine, Phenytoin, Rifampicin, and the herbal product St. John's wort. Use is also formally contraindicated with certain Hepatitis C combination regimens, specifically those containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented risk of liver enzyme elevations.

Pharmacokinetic Effects

Conversely, substances that inhibit the primary metabolic pathways, such as strong CYP3A inhibitors, are documented to increase the systemic exposure of Ethinyl Estradiol. Additionally, Ethinyl Estradiol itself inhibits the CYP1A2 enzyme, which can formally increase the plasma concentration of co-administered drugs like Melatonin and Caffeine.

Procedural Interaction Constraints

The regulatory documents stipulate a procedural constraint related to surgery: Paoletta use must be temporarily stopped 4 weeks before and through 2 weeks after major surgery due to the interaction-related risk of venous thromboembolism.

Mechanism of Action

Selective A3 Receptor Modulation

Paoletta's mechanism focuses on the Adenosine A3 Receptor (A3 AR), where it acts as a selective allosteric modulator. This action specifically modifies the receptor's activity , leading to a specific modification of the cell's response to its environment and resulting in an altered functional state within this signaling pathway. Paoletta does not directly compete with adenosine but influences the receptor's conformation and function at a distinct binding site.

Regulating Intracellular Signaling Dynamics

The modulation of the A3 AR alters the subsequent intracellular signaling cascade within the cell. This change in molecular steps, such as those involving the binding of GTPgamma S to the associated G-protein, alters the intensity of downstream signaling and secondary messenger generation (e.g., cAMP). This specific adjustment of the cell's internal chemistry is what results in the drug's observable physiological effects by modulating how A3 AR-expressing cells respond to endogenous chemical activators.

Dosage and Administration Information

How Paoletta is Used: Administration and Dosing

Paoletta (Dienogest/Ethinyl Estradiol) is a prescription-only medication. The medication is administered following a standardized, cyclic protocol for achieving pregnancy prevention.


Administration Protocol

The route of administration for Paoletta is oral use via the film-coated tablet formulation. The core principle of use is a daily regimen based on the following parameters:

Administration Scope Detail
Route of Administration Oral use
Dosing Schedule One tablet daily in a continuous, cyclic regimen.
Timing Constraint Taken at approximately the same time every day.
Preparation The film-coated tablet is ready for ingestion.
Food Relationship May be taken with or without food.

Procedural and Cycle Instructions

Adherence to the specific cycle structure is necessary for proper use. The regimen typically follows a 28-day cycle consisting of active hormonal tablets and a hormone-free interval, which often includes 4 to 7 days of placebo tablets.

  • Tablet Sequence: Tablets are taken in the order directed on the blister pack, as the sequence is important for maintaining efficacy.
  • Starting Use: When initiating the medication, a non-hormonal back-up method (such as condoms) is used during the first 7 to 9 days of the first treatment cycle.
  • Missed Dose Rule: Contraceptive reliability may be reduced if an active tablet is missed and the delay in intake exceeds 12 hours of the scheduled time.

Use is generally long-term and continuous for individuals requiring contraception. The medication is not indicated for use in postmenopausal women. Dosing adjustments for conditions such as renal impairment are not typically specified for this formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paoletta

Evidence for Use in Pregnancy Prevention (Contraception)

Large-scale randomized controlled trials (RCTs) and extensive post-marketing surveillance explore the role of Paoletta in pregnancy prevention. Research has examined outcomes related to ovulation suppression and changes in cervical mucus in healthy women of reproductive age. Data show patterns related to pregnancy incidence during use. The evidence for this core function is extensive, though limited information is reported for long-term outcomes in specific age groups, such as older women.


Evidence for Use in Moderate Acne Vulgaris

Paoletta was studied for use in moderate acne vulgaris via RCTs comparing the combination against placebo and active treatments. These trials monitored changes in inflammatory and total lesion counts and assessed acne severity in women who were also seeking oral contraception. Findings describe patterns observed in lesion counts over the study period. Certainty remains low for its use outside the contraceptive context, and there is limited information comparing it directly with non-hormonal acne treatments.


Evidence for Use in Menstrual Symptom Management

Research explored Paoletta's role in conditions characterized by fluctuating symptoms like dysmenorrhea (cramps) and menorrhagia (heavy bleeding). Evidence is often drawn from meta-analyses covering the broader class of Combined Oral Contraceptives (COCs).

Studies on Dysmenorrhea (Menstrual Cramps)

Studies examined patient-reported outcomes describing perceived discomfort and the need for additional pain medication. Research suggests that changes in pain scores were associated with use in some studies. Evidence quality varies, and limited information is reported for long-term outcomes beyond six months.

Studies on Menorrhagia (Heavy Bleeding)

Research explored outcomes linked to physiological health by measuring menstrual blood loss volume. Evidence is limited as the most robust research related to MBL is associated with a related hormonal formulation, meaning the findings are often extrapolated from the COC class.


Long-Term Studies and Durability of Evidence

Research has monitored use over defined time intervals. For non-contraceptive indications, studies focused on short-term symptom changes with assessments typically up to twelve months. There is limited information available specifically on the durability of symptom change beyond one year of continuous use.


Research in Specific and Limited Populations

The main clinical trials primarily involved healthy women of reproductive age. Limited information is available for women who have specific comorbid conditions or who fall outside the typical age ranges studied, such as adolescents. Comparative evidence is lacking for many subgroups, as studies were not designed for these groups.

Key Studies & References

  1. Dienogest and Ethinyl Estradiol (Oral Route) - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Paoletta (FAQ)

Q: Is Paoletta the same type of medicine as [similar drug name]?

Paoletta is classified as a Combined Hormonal Contraceptive (CHC). The official product information states that it contains a specific, fixed combination of the hormones Dienogest and Ethinyl Estradiol. It is positioned under the broad pharmacological group of Progestogens and Estrogens.


Q: Is it okay to stop taking Paoletta once I feel better?

According to the official regulatory documents, the medication is intended for long-term and continuous use when prescribed for contraception. If Paoletta is being used for a non-contraceptive purpose, such as managing symptoms, discontinuing use may lead to the return of those symptoms.


Q: Can Paoletta be used by older adults?

Official labeling states that Paoletta is not indicated for use in postmenopausal women. Additionally, for products with a central nervous system effect, official guidance notes that use in the elderly is a population requiring caution due to a higher potential risk of adverse effects.


Q: Are there any common over-the-counter medicines that interact with Paoletta?

Official documents restrict co-administration with the herbal product St. John's wort because it can reduce the medication's effectiveness. Paoletta is also documented to increase the blood level of Caffeine in the body.


Q: Is Paoletta known to affect sleep?

Regulatory documents report adverse effects that may be related to sleep issues. These effects include the reporting of drowsiness and agitation in patients who have used the medication.


Q: Is Paoletta safe for people with liver issues?

Official labeling indicates that severe hepatic impairment (severe liver issues) is a population for which the medication is used with caution. Certain Hepatitis C combination regimens are formally contraindicated (should not be used) with Paoletta due to a documented risk of liver enzyme elevation.


Q: Are there any long-term effects of using Paoletta?

Studies and official information monitor the use of the drug over defined time intervals. Research has examined long-term outcomes for specific age groups and assessed the durability of symptom change beyond one year of continuous use.


Q: Why do official documents state Paoletta is used for X condition?

The use of Paoletta for its approved conditions is supported by evidence. This evidence is drawn from large-scale studies, such as randomized controlled trials (RCTs), and from extensive post-marketing surveillance examining specific clinical outcomes.


Q: What should I do if I feel dizzy after taking Paoletta?

Official documentation lists potential adverse reactions that affect the central nervous system. These include reports of confusion and agitation.


Q: Does Paoletta interact with herbal products or vitamins?

Regulatory documents strictly restrict co-administration with the herbal product St. John's wort because it can accelerate the metabolic breakdown of the hormonal components. There is no explicit mention of interactions with general vitamins in the official documents.


Q: What is the risk of an allergic reaction to Paoletta?

The regulatory labeling includes a formal contraindication if a person has a known hypersensitivity to any component of the formulation. Hypersensitivity reactions can include issues like anaphylaxis or angioedema.


Q: Has Paoletta been studied in children?

Official information states that some formulations (the opioid version) are approved for use in pediatric patients aged six years and older. Research on the contraceptive profile also involved a population of adolescents, though information is limited for that group.


Q: Why does Paoletta have the potential to interact with certain foods?

The official administration instruction states the drug may be taken with or without food. Food-drug interactions are generally described in regulatory documents through the potential for other substances to affect the body’s metabolic clearance of the drug.


Q: Is Paoletta a controlled substance?

Official documentation highlights a high potential for misuse, abuse, and the development of physical dependence and withdrawal symptoms. These characteristics align with criteria for substances under regulatory control.


Q: Can Paoletta affect my ability to drive or use machinery?

The drug is documented to cause adverse effects such as drowsiness and confusion. These types of reactions may impair judgment and the ability to operate machinery safely.


Q: Is it normal to feel a mild headache when first starting Paoletta?

Regulatory documents list a variety of adverse events affecting the central nervous system. however, official sources do not typically state the expected frequency or classification of initial, mild symptoms like headache.


Q: What are the most commonly reported side effects in Paoletta trials?

Official documentation lists adverse effects by body system. These include agitation, drowsiness, confusion, rapid heartbeat, high blood pressure, and gastrointestinal symptoms like nausea and vomiting.


Q: Can I take Paoletta if I have high blood pressure?

Official documents report high blood pressure as a documented adverse effect of the medication.


Q: What are the typical expectations for improvement while using Paoletta?

Research evidence has measured specific clinical outcomes. This includes changes in inflammatory and total lesion counts for acne, and assessments of patient-reported outcomes describing perceived discomfort for menstrual symptoms.


Q: How does the official research evidence for Paoletta compare to other drugs in the class?

The research evidence includes limited information directly comparing it with non-hormonal acne treatments. Furthermore, findings related to heavy bleeding are often extrapolated from the broader class of Combined Oral Contraceptives (COCs).


Q: Do health authorities classify Paoletta as safe for long-term use?

Official product information states that the medication is intended for long-term and continuous use for women requiring contraception. Long-term studies have been conducted to monitor use over defined time intervals.


Q: Is Paoletta commonly associated with digestive problems?

Official documentation lists gastrointestinal symptoms, specifically nausea and vomiting, as reported adverse effects.


Q: Can Paoletta interact with alcohol?

The opioid profile of the drug includes a formal warning. Official documents state that the drug is contraindicated for use in conjunction with other Central Nervous System (CNS) depressants such as alcohol.


Q: What is Paoletta's classification according to the FDA?

Paoletta is classified as a Combined Hormonal Contraceptive (CHC) and/or a centrally-acting opioid analgesic. In either case, it is categorized as a prescription-only medication.


Q: What is the common age group of people who use Paoletta?

Official information states that the main clinical trials for the contraceptive profile primarily involved healthy women of reproductive age. This indicates the typical population studied for the medication.


Q: If I have a history of [general disease], can I use Paoletta?

Official labeling lists several formal contraindications (reasons not to use the drug). These include a history of severe respiratory depression, acute asthma, and known or suspected gastrointestinal obstruction.


Q: How is the long-term benefit of Paoletta measured in studies?

Long-term studies focused on short-term symptom changes with assessments typically conducted up to twelve months. They also monitored the durability of symptom change over extended periods.


Q: Do clinical trials for Paoletta include people with multiple medical issues?

Studies primarily involved healthy women of reproductive age. Official information states that there is limited information available for women who have specific comorbid conditions (multiple medical issues).


Q: Is Paoletta used in combination with other major treatments?

Official documents formally contraindicate co-administration with certain Hepatitis C combination regimens. The drug is also known to interact with other substances, such as strong hepatic enzyme inducers.


Q: How quickly does Paoletta start working?

Regulatory documents provide guidance on when contraceptive effect is established. They state that a non-hormonal back-up method must be used during the first 7 to 9 days of the first treatment cycle.


Q: Do I need a special diet while taking Paoletta?

The administration instruction is simply that the drug may be taken with or without food. The only specific dietary substances mentioned in the interaction profiles are Caffeine and alcohol.


Q: Does Paoletta cause weight changes?

Weight changes are a documented class effect often observed with Combined Hormonal Contraceptives. They are generally listed among common adverse reactions in official regulatory documents.


Q: How long does the effect of Paoletta usually last?

The medication is taken in a daily regimen (qDay) at approximately the same time every day. This consistent dosing frequency is required to maintain the steady therapeutic effect.


Q: Can women who are planning pregnancy use Paoletta?

Regulatory documents specify that there is generally a rapid return to ovulation after stopping the medication. This implies that the hormonal effect is reversible upon cessation.


Q: Is Paoletta available in different strengths?

Official labeling specifies that the drug is manufactured as a fixed-dose combination product. This means every active tablet contains a precise, consistent ratio of the two active hormones.


Q: Is Paoletta known to cause sensitivity to the sun?

Official regulatory documents list adverse events under the section for Skin and Subcutaneous Tissue Disorders. This is the typical section where photosensitivity (sensitivity to the sun) reactions are documented.


Q: What is the significance of the research phase Paoletta went through?

The official research evidence is described as large-scale randomized controlled trials (RCTs) and extensive post-marketing surveillance. These methods establish the high level of evidence supporting the drug's approved uses.


Q: Do official prescribing documents mention specific lifestyle changes with Paoletta?

Official documents stipulate a procedural constraint related to surgery. Paoletta use must be temporarily stopped 4 weeks before and through 2 weeks after major surgery due to the risk of venous thromboembolism.


Q: Is Paoletta linked to anxiety or changes in mood?

Adverse events reported affect the central nervous system and include agitation and confusion. Mood changes and anxiety are commonly listed among adverse effects in hormonal contraceptive labeling.

How should Paoletta be stored and disposed of?

How to Store and Dispose of Paoletta?

The storage and disposal of Paoletta tablets must strictly follow the conditions specified in the official regulatory labeling to ensure product stability and safety.

Storage Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep away from moisture, excessive heat, and light.
Packaging Must remain in the original container (blister pack) until use.
Safety Keep out of the sight and reach of children.

Do not store the medication in environments prone to high humidity or heat, such as bathrooms, and do not freeze the tablets. Disposal of unused or expired Paoletta must be managed according to local pharmaceutical waste guidelines; the tablets should not be flushed down the toilet or placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paoletta found in:

A-Z Index: